Introduction
Light transmission aggregometry (LTA) is considered the reference standard of platelet function testing. The method was independently described in 1962 by Born [1] and O'Brien [2] . LTA measures the transmission of light in a citrated platelet-rich plasma (PRP), which increases when platelets are aggregated upon addition of various agonists (e. g. collagen, adenosine diphosphate [ADP], arachidonic acid [AA] and thrombin receptor activator peptide-6 [TRAP-6]) [3] . This laboratory method is a widely used robust diagnostic approach, particularly for detecting platelet function defects among individuals referred for inherited, acquired and iatrogenic (i.e. dual antiplatelet therapy) bleeding problems [4, 5] .
Light transmission aggregometry is considered to be technically challenging and time consuming. Many preanalytical and analytical influencing factors may affect this technique; therefore, specially trained staff are required to establish and carefully control this method [6] . Although LTA is used worldwide and has been for more than five decades now, it appears paradoxical that uniform methodological standardization is still lacking [7] . Results from a previous published worldwide survey in more than 350 clinical and research laboratories demonstrated extreme heterogeneity in LTA practices [8, 9] . At least 46% of the laboratories performed LTA on patient samples without control samples [8] . This finding is in agreement with an earlier published study about platelet function testing practices among participants of the United Kingdom National External Quality Assessment Scheme (UK NEQAS) for Blood Coagulation, which showed the lack of quality control programs in many cases [10] .
The Clinical and Standards Institute (CSLI) guideline on platelet function testing [11] , which was published after these survey findings, recommends that each laboratory should run healthy control samples in parallel with patient samples on each day. Moreover, the guidelines of the British Committee for Standards in Hematology (BCSH) [12] propose repeating all unexpected, abnormal LTA tests with a fresh sample, in parallel with a normal control sample. It is evident that, in particular, an internal quality control (IQC) is required to evaluate and improve the analytical performance and validity of platelet function testing. However, standardized commercially available control material for IQC of LTA is still not available [13] .
Until recently we acquired normal control samples for IQC from healthy staff members of our highly specialized hemostasis laboratory, but the use of laboratory staff as normal blood donors for IQC material is difficult, particularly for small laboratories, where 'volunteers' are in short supply. Continuous regular invasive procedures raise also several health concerns and ethical and legislative issues [13, 14] . In laboratories that provide LTA on five consecutive workdays (from Monday to Friday), at least one fresh blood collection (20 -25 mL) must be performed with one employee or one healthy volunteer on each workday [14] . These reported frequencies and blood volumes necessary for IQC measurements of LTA are of ethical concern. If 21 IQC measurements per month are assumed, a minimum of 5-6 L of whole blood would have to be collected within 1 year. Limited numbers of voluntary employees, staff members feeling compelled to provide blood, injury of the body's integrity by repeated venipuncture and complications of blood donation, such as thrombophlebitis or latent iron deficiency (ID), must be considered. It is well known that whole blood donations are associated with low serum ferritin values and ID [15] [16] [17] , particularly in female and frequent donors [18] .
For the stated reasons, we considered an alternative strategy for acquisition of IQC material for platelet function testing. This study aimed to evaluate the implementation of buffy-coat-derived pooled platelet concentrates (PCs) as IQC material for LTA. One pooled PC per work-week was consecutively aliquoted from the original storage bag in four baby bags, which were used to perform daily IQC (from Monday to Friday) on a four-channel Chronolog 700 Aggregometer (Chronolog Corporation, Havertown, Pennsylvannia, USA). Platelet aggregation was induced with collagen, ADP, AA and TRAP-6. In routine clinical practice we focused only on these four agonists in order to address satisfactory responsiveness to acetylsalicylic acid, clopidogrel, prasugrel, ticagrelor, and latterly cangrelor [6, 12] .
Materials and methods

Ethics
This study was carried out in accordance with the latest version of the Declaration of Helsinki (Fortaleza 2013) and is in accordance with the recommendations of the Ethical Committee of the Medical University of Graz (Graz, Austria).
Preparation of buffy-coat-derived pooled platelet concentrates (PCs) for internal quality control (IQC) material for light transmission aggregometry (LTA)
On each weekend (Saturday), one fresh pooled PC (from four to five healthy blood donors) was manufactured at the University Clinic for Blood Group Serology and Transfusion Medicine of the Medical University of Graz (Graz, Austria). It was carefully prepared from four to five buffy-coats of blood donors and additive solution (platelet additive solution SSP+, Macopharma, Tourcoing, France). After leukocyte-depletion by filtration, the pooled PC (> 200 mL) was aliquoted on a daily basis in five baby bags (40-50 mL). At least one baby bag per day on four consecutive workdays (Monday to Thursday), and the original storage bag (on Friday), were prepared and delivered from the blood bank to the core laboratory from Monday to Friday. The lot number of the baby bags and the original storage bag changed weekly. In detail, 450 mL of whole blood was collected and mixed with 63 mL anticoagulant CPD (citric acid 3.27 g, trisodium citrate 26.3 g, sodium phosphate 2.51 g, dextrose 25.5 g, Water for injection 1000 mL) in a topbottom bag (MacoPharma International GmbH, Langen, Germany) on day 0 (Friday). Whole blood units were then cooled down to 22 AE 2°C by using 1,4-butanediol cooling plates immediately after collection, stored overnight at ambient temperature, centrifuged on day 1 (Saturday) by hard spin centrifugation (4247 9 g, 13:30 min) and separated by LUXOmatic (LMB Technologie GmbH, Schwaig, Germany).
After separating plasma and red blood cells the remaining buffy coats (BCs) from donors with at least 200 9 10 9 L À1 platelets were rested for at least 2 h. Four 4.05 g. Water for injection 1000 ml, pH 7.2, MacoPharma, International GmbH). The pool was centrifuged with a soft spin program (320 9 g, 6 min) and separated again automatically by LUXOmatic. The platelet-rich supernatant was then leuco-reduced (WBC < 1 9 10 6 / unit) and stored in 'Compostop flex 2F plt proc. Leuko red' storage bags (Fresenius Hemocare Austria, Eugendorf, Austria), resulting in a leuco-reduced platelet concentrate in additive solution with a plasma portion of one-third [19] .
The platelet concentrates were stored in the Fresenius storage bags on a platelet agitator (TA-1; Sarstedt, Wiener Neudorf, Austria) within a climate cabin at 20-24°C (TI-3; Sarstedt) and agitated at a rate of 60/min. The original storage bag was aliquoted into a baby bag (4BBSK100E, Fresenius Hemocare Austria) under sterile conditions on a daily basis from day 3 until day 6, and on day 7 (Friday) the remaining content of the original storage bag was used for the IQC measurements.
Internal quality control (IQC) measurements
The study period for this proof of concept study was from the end of September 2014 to the end of April 2016. These data comprised 85 work-weeks (from Monday to Friday) or in other words 85 different lots. In our laboratory, the aliquoted four baby bags and the original storage bag, which represented platelet rich plasma (PRP), were decanted in 15mL Eppendorf Conical Tubes Ò (Eppendorf Austria GmbH, Vienna, Austria). To obtain high-quality platelet-poor plasma (PPP; ≤ 10 9 10 3 lL À1 ) for blank value determination, aliquots were centrifuged at 2800 9 g (Eppendorf 5804 Centrifuge; Eppendorf Austria GmbH) for 15 minutes at room temperature [20, 21] . The platelet count with the PRP as well as the PPP was determined on the XE-2100 and the XE-5000 hematology analyzers (both Sysmex Corporation, Kobe, Japan).
Light transmission aggregometry (LTA)
LTA was performed on a four-channel Chronolog 700 Aggregometer (Chronolog Corporation). After pipetting 450 lL unadjusted PRP in each channel, aggregation was induced with 5 lL collagen (type I) from equine tendons (concentration 1 mg mL
Chronolog Corporation [22] ), 5 lL adenosine 5 0 -diphosphate (ADP) (concentration 10 mM; Sigma-Aldrich Handels GmbH, Vienna, Austria), 5 lL of arachidonic acid (AA) (concentration 50 mM, CHRONO-PAR Ò Arachidonic Acid; Chronolog Corporation) and 20 lL of thrombin receptor-activated peptide 6 (TRAP-6) (concentration 1 mM; Bachem Distribution Services GmbH, Weil/Rhein, Germany). The within-run coefficients of variation (CVs) were calculated based on a 10-fold measurement of PRP samples of pooled PCs. The between-run CVs were determined with pooled PCs based on measurement on five consecutive workdays (Monday to Friday) [23] .
Statistical analysis
Data distribution was calculated with the KolmogorovSmirnov test. Normally distributed data were described in means AE standard deviation (SD). Not normally distributed data were described in medians (interquartile range [IQR] ). According to the literature [24, 25] , for subgroup comparisons of metric variables in the case of normal distribution the paired Student's t-test was calculated (between days from Monday to Friday), and for metric non-normal distributed variables the exact Mann-Whitney U-test was used. For all four agonists used (i.e. collagen, ADP, AA and TRAP) and platelet counts (i.e. PRP and PPP) reference ranges were reclassified for normal distributed variables (mean AE 2*SD) and for non-normal distributed variables (2.5-97.5 percentiles), respectively. SPSS Statistics for Windows version 22.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis.
Results
Data for IQC measurements, including reclassified reference ranges for pooled PCs and platelet counts (from Monday to Friday; overall 85 weeks), are shown in Fig. 1 and Table 1, respectively. Collagen-, ADP-and AA-induced values and PPP platelet count were not normally distributed and were presented as medians (IQR) and reference ranges (2.5-97.5 percentiles), respectively. The TRAP-6-induced values and the PRP platelet count were normally distributed and were shown as means AE SD and reference ranges (mean AE 2*SD), respectively. Differences in responsiveness of each agonist between days are shown in Table 1 .
Discussion
Previous published guidelines and recommendations on LTA measurements require methodology standardization in clinical practice [6, 11, 12, 26] but do not cover IQC implementation or test interpretation in detail [27] . In contrast, the present report aims to present in detail how one institution implemented a new strategy for IQC of measurement of platelet function testing in daily clinical practice. To the best of our knowledge, this is the first study reporting buffy-coat-derived pooled PCs as a potential material for IQC for hemostasis laboratories.
Several advantages of this procedure may be considered. First of all, it provides an approach to standardization of IQC material in platelet function testing. The adequacy of the laboratory equipment, including the test reagents and the aggregometer, can be assessed and controlled. Secondly, one pooled PC can be used as aliquoted IQC material on five consecutive workdays (from Monday to Friday). This practice provides the same source material with a consistent platelet count on different days. In contrast, daily de novo blood donations from different staff members may cause inconsistent IQCs with a different platelet count each day, apart from the ethically untenable situation for employees [14] .
An additional benefit of this approach to IQC measurements is the recycling of buffy-coat, which is a by-product of whole blood donations in blood banks. Buffy-coatderived pooled PCs serving as high-quality IQC material for LTA maximize the clinical use of the valuable and very important whole blood donations.
With the previously used procedure for IQC acquisition in our laboratory, four employees (normal 'volunteers') would undergo about 252 blood donations with a minimum blood volume of 5040 mL yearly. By comparison, one single unit of blood taken during a whole blood donation in blood banks is about 450 mL [28] . That implies that yearly about 11 whole blood donations (450 mL 9 11.2 = 5040 mL) from altogether four staff members would be performed in the laboratory. In other words, each employee would undergo blood draw (20-25 mL) on 63 workdays each year. This procedure is critical in daily laboratory practice. Personnel safety takes top priority in national and international employee protection regulations. In present times repeated blood draws from a peripheral vein of employees without diagnostic or therapeutic benefit must be brought into question. Herein, we demonstrate a new and practicable alternative strategy to apply an appropriate IQC material for LTA. Running IQCs with buffy-coat-derived pooled PCs in parallel with patient samples would be beneficial for both patients' and employees' safety, although the stored pooled PCs show physiological decreasing responsiveness to the used agonists from Monday to Friday, reaching some statistical significance (Table 1 ) but without diagnostic and therapeutic relevance [29] .
Platelet function testing remains challenging with regards to ensuring accurate and meaningful results. The major problem concerning this method is the difficulty in simulating hemostasis in vitro. Platelets are inherently prone to artefactual in vitro activation but also to desensitization [30] . In clinical practice, the PRP is often adjusted with autologous PPP to achieve a standardized platelet number (typically 200 9 10 9 L À1 to 300 9 10 9 L
À1
) [31] . This time-consuming procedure may affect platelet activation and has been questioned, because it does not reflect the platelet function in vivo [32] [33] [34] [35] . A previous prospective cohort study of patients undergoing elective percutaneous coronary intervention with stent implantation demonstrated that both native and platelet count-adjusted PRP had equal ability to predict adverse clinical outcomes [36] . A prospective cohort study by Castilloux et al., which comprised 67 individuals with different definite bleeding disorders, concluded that the LTA with native PRP was not inferior to the LTA performed with adjusted PRP in clinical practice [37] . In another study, adjustment of PRP was shown to be of no advantage, and thus for standardization of LTA not necessary [33] . These authors avoided the practice of diluting PRP with PPP in their LTA method to prevent artefactual activation of platelet aggregation.
Herein, we reclassified reference ranges for pooled PCs (buffy coats from four to five healthy blood donors) based on 85 weeks. In accordance with reference ranges in healthy volunteers previously published by Hayward et al. [24] , collagen, ADP and AA-induced aggregation results were not normally distributed in stored pooled PCs. The different results come from the different age of the analyzed platelets (from healthy volunteers [24] versus stored pooled PCs [29] ) and the varying agonist concentrations applied.
One of the main issues of standardization of LTA in clinical routines remains the introduction of a functionally adequate control material to allow accurate, reproducible testing of platelet function [13] . The availability of stabilized IQC material for tests that are based on whole blood or cellular systems (including platelet function testing) is limited [38] . Pooled PCs manufactured in blood banks are a commercially available source of IQC material for small laboratories endeavoring to undertake quality control procedures for platelet function testing.
Three major limitations of this study remain. Firstly, the authors cannot completely rule out that some voluntary blood donors have taken acetylsalicylic acid or non-steroidal anti-inflammatory drugs by mistake in the days before blood donation, influencing collagen-and AA-induced IQC measurements. Nutritional polyphenols may also influence platelet aggregation [39] . Secondly, distinct reduced ADP-activated platelet aggregation in stored platelet concentrates is already observed after 24 h [40] , increasing variance (CV) of ADP-activated IQC measurements near zero values (% aggregation and AUC). Higher doses of ADP may overcome this major limitation and increased amount of plasma in the storage solution reduces deterioration of platelet responsiveness to ADP, as reported by Keuren et al. [41] . In order to optimize the production process, local blood banks use a minimum of plasma in the platelet concentrates. Thirdly, we focused on a limited panel of agonists necessary to test dual antiplatelet therapy. In further studies this concept may be extended to other agonists used in specialized platelet function testing (i.e. epinephrine, ristocetin and ATP release).
In conclusion, buffy-coat-derived pooled PCs serve as a reliable and robust high-quality IQC material for LTA measurements. We recommend that platelet function testing using LTA is performed in laboratories or clinical centers, where access to blood banks is well established, to avoid the burden of unnecessary blood donation for employees.
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